DRUG resistance of tumor is a very common phenomenon in clinical tumor treatment. Most patients with lung cancers, one of the most common malignant tumors in China, have no response to chemotherapy, so it is very impo...DRUG resistance of tumor is a very common phenomenon in clinical tumor treatment. Most patients with lung cancers, one of the most common malignant tumors in China, have no response to chemotherapy, so it is very important to study the resistant biology of lung cancer for treatment. The rate of drug sensitivity in non-small cell lung cancer (NSCLC) is lower than in small cell lung cancer (SCLC). The drug resistance, besides the effects of MDR1 gene and GST-π, is also closely correlated with the effect of another novel gene MRP (multidrug resistance-related gene).In the previous study on a doxorubicin-selected human NSCLC cell line, GAOK, we found that MDR1 gene overexpressed and MDR1 antisense RNA mediated by retrovirus could not completely reverse the phenotype of multidrug resistance, and展开更多
文摘DRUG resistance of tumor is a very common phenomenon in clinical tumor treatment. Most patients with lung cancers, one of the most common malignant tumors in China, have no response to chemotherapy, so it is very important to study the resistant biology of lung cancer for treatment. The rate of drug sensitivity in non-small cell lung cancer (NSCLC) is lower than in small cell lung cancer (SCLC). The drug resistance, besides the effects of MDR1 gene and GST-π, is also closely correlated with the effect of another novel gene MRP (multidrug resistance-related gene).In the previous study on a doxorubicin-selected human NSCLC cell line, GAOK, we found that MDR1 gene overexpressed and MDR1 antisense RNA mediated by retrovirus could not completely reverse the phenotype of multidrug resistance, and
